Latest News

A new survey has discovered a gap between the value parents place on children's vision and the comprehensive eye care that teens and young adults receive.

A recap of the FDA approvals, phase 3 readouts, and pipeline data that shaped diabetic eye disease care in the first half of 2026.

Esen Akpek, MD, on dry eye's emotional and vision-related toll, its hidden autoimmune links, and when to move patients beyond artificial tears.

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

Antineoplastics were the most frequently implicated drug class in review

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for the treatment of wet AMD.

The FDA issued a nationwide recall of a steroid eye drop.

From a phase 3 durability readout for a first-in-class TKI to a new interchangeable ranibizumab biosimilar and a deep dive into geographic atrophy management, June brought a wide-ranging mix of regulatory, clinical, and practice-pattern news for retina specialists

Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.

A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.